[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-459429-105":59,"doc-detail-459429-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","glial-interaction-with-parkinsonian-disorders-biomarkers-poster-presentation-alpha-synuclein-dopaminergic-dysfunction-and-clinical-stages","Glial interaction with Parkinsonian disorders biomarkers - Poster presentation - alpha-synuclein, dopaminergic dysfunction and clinical stages","","Background: The neuronal α-Synuclein disease proposes biological anchors for Parkinson’s disease, combining neuronal α-synuclein pathology and dopaminergic neuronal dysfunction; however, glial-cell interactions with α-syn pathology remain unclear. Method: Using the Parkinson’s Progression Markers Initiative (PPMI) database, cerebrospinal fluid glial biomarker measures were analyzed with Rv4. Biological anchors were αS (Amprion-αS-SAA) and dopaminergic dysfunction (DaTscan interpretation; putamen lowest SBR). CSF GFAP, sTREM2, YKL40 and S100 were compared with clinical and cognitive variables including sex, education, Hoehn & Yahr (HY) and MDS-UPDRS. Result: In 268 participants (67 controls, 201 PD), S+D+ showed worse MDS-UPDRS and lower MoCA. CSF YKL-40 associated with both S and D and with HY. In S+ individuals, CSF GFAP interacted with DaT putamen SBR and HY. Conclusion: CSF YKL-40 may represent an early event in PD α-syn pathology, while CSF GFAP may relate to functional independence in S+.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/glial-interaction-with-parkinsonian-disorders-biomarkers-poster-presentation-alpha-synuclein-dopaminergic-dysfunction-and-clinical-stages/459429/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/glial-interaction-with-parkinsonian-disorders-biomarkers-poster-presentation-alpha-synuclein-dopaminergic-dysfunction-and-clinical-stages/459429.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which glial markers were measured in cerebrospinal fluid?","Question",{"text":112,"@type":113},"CSF glial biomarkers included GFAP, sTREM2, YKL40, and S100, measured using the Roche NeuroTool Kit.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the biological anchors of α-synuclein and dopaminergic dysfunction assessed?",{"text":117,"@type":113},"The α-synuclein anchor S was assessed by Amprion-αS-SAA. Dopaminergic dysfunction D was assessed by DaTscan visual interpretation and the putamen’s lowest SBR value.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about CSF YKL-40 and clinical staging?",{"text":121,"@type":113},"CSF YKL-40 associated with both S and D and also with Hoehn & Yahr (HY) scores, suggesting relevance to clinical staging in Parkinson’s disease.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},459429,1790755905,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":52,"preview_page_count":19,"preview_urls":143},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10. 1002/alz70856_106159  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nGlial interaction with Parkinsonian disorders biomarkers:  \nalpha-synuclein, dopaminergic dysfunction and clinical stages  \nLara Angi Souza1  Daniel Teixeira Wyllians Vendramini Borelli5, 7, 8, 9   \ndos Santos2, 3  Eduardo R. Zimmer4, 5, 6 Artur Francisco Schumacher-Schuh 10  \n1 Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, Porto Alegre, RS, Brazil  \n2 Neurology Department, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil  \n3 Neurology Department, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil  \n4 Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil  \n5 Brain Institute of Rio Grande do Sul (InsCer), PUCRS, Porto Alegre, Rio Grande do Sul, Brazil  \n6 McGill Centre for Studies in Aging, Montreal, QC, Canada  \n7 Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil  \n8 Centro de Memória, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil  \n9 Clinical Hospital of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil  \n10 Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil  \nCorrespondence  \nLara Angi Souza, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, Porto Alegre, RS, Brazil.  \nEmail: [lara11angi@gmail.com](lara11angi@gmail.com)  \nAbstract  \nBackground: The neuronal α-Synuclein disease (NSD) has been recently proposed to identify biological anchors of Parkinson’s disease, comprehending neuronal alphasynuclein (S) and dopaminergic neuronal dysfunction (D). However, interactions with glial cells are still poorly understood in the context of α-syn pathology. In this study, we investigated the relationship between glial markers and PD pathophysiology, specifically to identify which glial markers have stronger association.  \nMethod: The Parkinson’s Progression Markers Initiative (PPMI) database was used to retrieve cerebrospinal fluid (CSF) glial biomarkers measures. Biological anchor S was assessed by Amprion-αS-SAA (Figure 1a-d) and D as assessed with DaTscan visual interpretation and Putamen’s lowest SBR value. CSF GFAP, STREM2, YKL40 and S100 were measured using Roche NeuroTool Kit. Clinical and cognitive variables collected included sex, years of education, Hoehn & Yahr scale (HY) and the total MDS-UPDRS data. Group comparisons were analyzed using Chi-squared test and ANOVA. General linear models adjusted for age were conducted to evaluate the association of glial markers, biological anchors, and HY. All statistical analyses were performed in Rv4. Result: A total of 268 individuals (67 controls and 201 PD) were evaluated (mean age 61.4± 10. 3 years, Tab. 1). Compared with S-D-, S+D+ individuals had higher scoresworse levels of total MDS-UPDRS (p \u003C 0.001) and lower MOCA (p \u003C 0.001) scores. CSF YKL-40 levels were associated with S (beta = -0. 37, p = 0.02) and D biological anchors (b = -0. 37, p = 0.02, Figure 2b) adjusted for age. CSF GFAP, S100Band sTREM2 were not associated with S or D (p > 0.05). When evaluating clinical symptoms of PD with HY, CSF YKL-40 was associated with HY scores (beta = -0. 36, p = 0.02, Figure 2c). However, in S+ individuals, only CSF GFAP levels showed a significant interaction with DaT putamen SBP levels and HY scores (beta = 0. 65, p = 0.004).  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e106159.  \n[https://doi.org/10.1002/alz70856_106159](https://doi.org/10.1002/alz70856_106159)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of4  \nBIOMARKERS  \nConclus","cbCaig1nZYbDuK6I","https://ap.wps.com/l/cbCaig1nZYbDuK6I","pdf",1424211,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"Which glial markers were measured in cerebrospinal fluid?\",\"answer\":\"CSF glial biomarkers included GFAP, sTREM2, YKL40, and S100, measured using the Roche NeuroTool Kit.\"},{\"question\":\"How were the biological anchors of α-synuclein and dopaminergic dysfunction assessed?\",\"answer\":\"The α-synuclein anchor S was assessed by Amprion-αS-SAA. Dopaminergic dysfunction D was assessed by DaTscan visual interpretation and the putamen’s lowest SBR value.\"},{\"question\":\"What did the study find about CSF YKL-40 and clinical staging?\",\"answer\":\"CSF YKL-40 associated with both S and D and also with Hoehn \\u0026 Yahr (HY) scores, suggesting relevance to clinical staging in Parkinson’s disease.\"}]","Glial interaction with Parkinsonian disorders biomarkers - Poster presentation - alpha-synuclein, dopaminergic dysfunction and clinical stages | PDF",[144,148,152,156],{"page_no":8,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/925f356eb89bc1cc85ec0426bdde2814.webp",983,1291,{"page_no":14,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/180bd60f016c78099c0b4518ee01794a.webp",982,1290,{"page_no":81,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/c9e2f871f5ecc61d6c917703c969fac4.webp",981,1289,{"page_no":19,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/f39222e35d954b06525e10c955fe6912.webp",980,1287]